Scrip
US panel calls for phased launch of Neuromed/Covidien's long-acting opioid Exalgo
24 September 2009
Sue Sutter
Please Login to read the full article.
24 September 2009
Sue Sutter
The US FDA's outside advisors have generally endorsed a proposed risk evaluation and mitigation strategy (REMS) for
Neuromed Pharmaceuticals' opioid Exalgo (hydromorphone extended-release, licensed to
Covidien) but said the drug should be launched in a phased manner to test the scheme's...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Anti-obesity drugs: an inventor's perspective
- Basilea set for success as Toctino roll-out sees revenues surge
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
